---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-24-000106"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:37:23.343817+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M

## Summary
- Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.
- Adjusted EBITDA $11M (+630% YoY) vs -$2M in prior-year quarter.
- Clinical Services revenue $141M (+15% YoY); Advanced Diagnostics $23M (-3%).
- FY2024 guidance raised: revenue $655-667M (from $650-660M); adj. EBITDA $33-37M (from $21-24M).
- Cash and marketable securities $388M at quarter end.

## SEC filing metadata
- accession: 0001077183-24-000106
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000106/0001077183-24-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000106/neo-20240729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-24-000106
- JSON: https://secwatch.observer/filing/0001077183-24-000106.json
- Plain text: https://secwatch.observer/filing/0001077183-24-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.